Online inquiry

IVTScrip™ mRNA-Anti-ERBB2, ZW-25(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ16016MR)

This product GTTS-WQ16016MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets ERBB2 gene. The antibody can be applied in Ovarian Cancer research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001005862.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2064
UniProt ID P04626
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB2, ZW-25(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ16016MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4906MR IVTScrip™ mRNA-Anti-ACVR2, BYM338(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BYM338
GTTS-WQ4584MR IVTScrip™ mRNA-Anti-CD40LG, BMS-986004(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-986004
GTTS-WQ12247MR IVTScrip™ mRNA-Anti-CD274, MPDL3280A(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MPDL3280A
GTTS-WQ7611MR IVTScrip™ mRNA-Anti-CSF3R, G-CSF-Fc-PEG(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA G-CSF-Fc-PEG
GTTS-WQ13448MR IVTScrip™ mRNA-Anti-TNFRSF10B, PRO95780(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PRO95780
GTTS-WQ8940MR IVTScrip™ mRNA-Anti-IL1RL2, IL2 fused to diphteria toxin(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IL2 fused to diphteria toxin
GTTS-WQ4809MR IVTScrip™ mRNA-Anti-DPP4, BT 5/9(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BT 5/9
GTTS-WQ2903MR IVTScrip™ mRNA-Anti-IL17RA, AMG827(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AMG827
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW